Medically reviewed by Larysa Grevtsova, MD
bmiMD vs Embody: Which GLP-1 Provider Is Right for You?
bmiMD and Embody are both cash-pay telehealth platforms built around compounded GLP-1 medications, but they take noticeably different approaches — one leans into a broader wellness stack with flat, dose-independent pricing, and the other differentiates itself with a needle-free oral option and promotional intro rates. Here’s how they actually compare.
Medications and Formats
bmiMD offers compounded semaglutide and tirzepatide, including microdose versions of both — a lower-dose option positioned for metabolic wellness rather than aggressive weight loss, aimed at people who’ve had trouble tolerating standard GLP-1 doses or who aren’t chasing a specific weight target. bmiMD also offers additional protocols beyond GLP-1, including NAD+, B-12, Sermorelin, and Glutathione, positioning itself closer to a broader longevity and metabolic-health platform than a GLP-1-only provider.
Embody offers compounded semaglutide and tirzepatide as injections, plus a notable point of differentiation: an oral tirzepatide gum, one of the few needle-free tirzepatide formats available through telehealth. If injection aversion has been a barrier for you specifically, this is a meaningful practical difference between the two platforms.
Clinical Oversight
Both platforms route prescribing through licensed clinician networks rather than in-house doctors. bmiMD emphasizes same-day telehealth consultations with board-certified physicians and unlimited messaging with your prescribing provider. Embody prescribes through the CareGLP Affiliated P.C. network via the OpenLoop Health telehealth infrastructure, and visits may be live video or asynchronous form review depending on factors the company doesn’t fully disclose upfront — worth clarifying directly if a live visit matters to you. Embody displays a LegitScript certification seal, a third-party verification of telehealth and pharmacy compliance standards, and names a board-certified Chief Medical Officer.
Both source medication from licensed compounding pharmacies rather than dispensing FDA-approved finished products — as covered in our compounded vs. brand-name guide, this means neither bmiMD’s nor Embody’s medications have been individually approved by the FDA, even though both use the same active pharmaceutical ingredients found in Ozempic, Wegovy, Mounjaro, and Zepbound.
Pricing Structure
This is where the two platforms diverge most.
bmiMD uses a same-price-at-every-dose model tied to commitment length: pricing has been reported around $99/month on a 12-month prepaid plan, rising somewhat for shorter 6-month or 3-month commitments, with a higher month-to-month rate for no commitment at all. The price doesn’t change as your dose increases, which removes a common source of billing surprise on other platforms. bmiMD also advertises a money-back guarantee if you complete the consultation and aren’t approved for treatment.
Embody runs a promotional intro-rate model — reported starting prices for compounded semaglutide have been in the $79–99/month range and tirzepatide around $129–199/month, but these are promotional first-month rates that increase afterward unless you select their flat-rate plan (reported around $299/month), which holds steady regardless of dose. This structure means the advertised starting price and your actual ongoing cost can differ significantly, so confirming the maintenance-dose price before enrolling is especially important with Embody.
Neither platform bills insurance; both accept HSA/FSA payment. Exact current pricing should always be confirmed directly on each provider’s site, since promotional rates and plan structures change relatively often in this market — a pattern we cover more generally in our GLP-1 cost guide.
Cancellation and Commitment
bmiMD’s prepaid multi-month plans lock in pricing but represent a larger upfront financial commitment; its month-to-month option offers more flexibility at a higher per-month rate. Embody operates month-to-month with a reported 72-hour cancellation window before the next billing cycle, which is worth noting if you’re considering trying the program short-term.
Who Each Platform Tends to Suit
bmiMD may be a better fit if you’re interested in a broader metabolic wellness approach beyond GLP-1 alone, want predictable flat pricing regardless of dose, or are specifically interested in a lower-intensity microdose option.
Embody may be a better fit if needle aversion is a genuine obstacle for you and the oral gum format is appealing, or if you want to test compounded GLP-1 at a low promotional entry price before committing longer-term — as long as you go in with clear eyes about the price increase after the intro period.
Bottom Line
Both bmiMD and Embody are cash-pay compounded GLP-1 platforms with licensed clinician oversight, but they solve somewhat different problems: bmiMD focuses on flat, predictable pricing and a wellness-oriented feature set, while Embody’s standout is format flexibility, particularly its oral tirzepatide option. Confirm current pricing, medication availability in your state, and clinician visit format (live vs. asynchronous) directly with each provider before enrolling, since these details are the ones most likely to have changed since this comparison was written.
For a side-by-side look at these two alongside the other major GLP-1 telehealth providers, see our full comparison table.